PL2011486T5 - Farmaceutyczne kompozycje rifaksyminy - Google Patents
Farmaceutyczne kompozycje rifaksyminyInfo
- Publication number
- PL2011486T5 PL2011486T5 PL08252198.0T PL08252198T PL2011486T5 PL 2011486 T5 PL2011486 T5 PL 2011486T5 PL 08252198 T PL08252198 T PL 08252198T PL 2011486 T5 PL2011486 T5 PL 2011486T5
- Authority
- PL
- Poland
- Prior art keywords
- rifaximin
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical group OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title 1
- 229960003040 rifaximin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN968KO2007 | 2007-07-06 | ||
| EP08252158 | 2008-06-23 | ||
| EP08252198.0A EP2011486B2 (en) | 2007-07-06 | 2008-06-26 | Pharmaceutical compositions of rifaximin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL2011486T3 PL2011486T3 (pl) | 2013-01-31 |
| PL2011486T5 true PL2011486T5 (pl) | 2016-09-30 |
Family
ID=40091777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08252198.0T PL2011486T5 (pl) | 2007-07-06 | 2008-06-26 | Farmaceutyczne kompozycje rifaksyminy |
Country Status (8)
| Country | Link |
|---|---|
| EP (4) | EP2837378A1 (pl) |
| CY (1) | CY1113068T1 (pl) |
| DK (1) | DK2011486T3 (pl) |
| ES (3) | ES2905795T3 (pl) |
| HR (1) | HRP20120665T1 (pl) |
| PL (1) | PL2011486T5 (pl) |
| PT (1) | PT2011486E (pl) |
| SI (1) | SI2011486T1 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
| US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| EP2942053A1 (en) * | 2007-07-06 | 2015-11-11 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| ES2972135T3 (es) | 2008-10-02 | 2024-06-11 | Salix Pharmaceuticals Inc | Tratamiento de encefalopatía hepática usando rifaximina |
| US12285414B2 (en) | 2008-10-02 | 2025-04-29 | Salix Pharmaceuticals, Inc. | Methods of treating hepatic encephalopathy |
| NZ597080A (en) * | 2009-06-15 | 2014-02-28 | Salix Pharmaceuticals Ltd | Modulation of systemic exposure to rifaximin |
| UA110199C2 (xx) * | 2009-10-27 | 2015-12-10 | Lupin Ltd | Тверда дисперсія рифаксиміну |
| US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| GEAP202112996A (en) | 2010-07-12 | 2021-09-10 | Salix Pharmaceuticals Ltd Us | Formulations of rifaximin and uses thereof |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| EP2890366A1 (en) | 2012-08-28 | 2015-07-08 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at least one of them is in the form of mini-tablets |
| ES2621557T3 (es) * | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
| US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
| CA3038312A1 (en) * | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
| WO2018197538A1 (en) | 2017-04-26 | 2018-11-01 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
| US11129862B2 (en) | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
| CN108658673A (zh) * | 2018-06-27 | 2018-10-16 | 安徽瑞然生物药肥科技有限公司 | 一种用于缓释肥料的包膜材料及其制备方法 |
| CN109021187B (zh) * | 2018-08-24 | 2019-09-06 | 中山大学 | 玉米醇溶蛋白-聚磺基甜菜碱两亲性缀合物及其制备方法与应用 |
| US20220008494A1 (en) * | 2018-11-21 | 2022-01-13 | Neilos S.r.l. | Composition for use in the prevention and/or symptomatic treatment of irritable bowel syndrome |
| CN109663150B (zh) * | 2018-12-29 | 2022-01-14 | 广州贝奥吉因生物科技股份有限公司 | 一种心肌修复水凝胶材料及其制备方法 |
| WO2020208140A1 (en) | 2019-04-12 | 2020-10-15 | Sandoz Ag | Rifaximin-containing granules |
| CN114401721A (zh) * | 2019-09-24 | 2022-04-26 | 博士医疗爱尔兰有限公司 | 利福昔明液体制剂 |
| CN111317824B (zh) * | 2020-02-29 | 2022-04-12 | 复旦大学 | 一种载多肽药物的口服纳米制剂及其制备方法 |
| AU2021298178A1 (en) * | 2020-06-26 | 2023-02-02 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
| US20240415809A1 (en) * | 2021-10-19 | 2024-12-19 | Zydus Lifesciences Limited | Pharmaceutical combinations |
| GR1010652B (el) * | 2023-04-20 | 2024-03-12 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιμικροβιακο παραγοντα και μεθοδος για την παρασκευη αυτου |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| IT1253711B (it) * | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali |
| IT1264494B1 (it) † | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
| ITMI20032144A1 (it) * | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| ITMI20041295A1 (it) † | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| US20060045865A1 (en) † | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
-
2008
- 2008-06-26 PL PL08252198.0T patent/PL2011486T5/pl unknown
- 2008-06-26 EP EP14186563.4A patent/EP2837378A1/en not_active Withdrawn
- 2008-06-26 PT PT08252198T patent/PT2011486E/pt unknown
- 2008-06-26 ES ES20160395T patent/ES2905795T3/es active Active
- 2008-06-26 SI SI200830741T patent/SI2011486T1/sl unknown
- 2008-06-26 ES ES11176043T patent/ES2798253T3/es active Active
- 2008-06-26 EP EP08252198.0A patent/EP2011486B2/en active Active
- 2008-06-26 EP EP20160395.8A patent/EP3714878B1/en active Active
- 2008-06-26 DK DK08252198.0T patent/DK2011486T3/da active
- 2008-06-26 EP EP11176043.5A patent/EP2420226B1/en active Active
- 2008-06-26 ES ES08252198.0T patent/ES2389358T5/es active Active
-
2012
- 2012-08-17 HR HRP20120665AT patent/HRP20120665T1/hr unknown
- 2012-08-23 CY CY20121100760T patent/CY1113068T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2389358T5 (es) | 2016-01-19 |
| ES2798253T3 (es) | 2020-12-10 |
| EP2011486B1 (en) | 2012-05-23 |
| EP3714878B1 (en) | 2022-01-19 |
| CY1113068T1 (el) | 2016-04-13 |
| EP2011486B2 (en) | 2015-08-12 |
| ES2905795T3 (es) | 2022-04-12 |
| EP2420226A1 (en) | 2012-02-22 |
| PT2011486E (pt) | 2012-08-24 |
| SI2011486T1 (sl) | 2012-10-30 |
| ES2389358T3 (es) | 2012-10-25 |
| EP2837378A1 (en) | 2015-02-18 |
| PL2011486T3 (pl) | 2013-01-31 |
| DK2011486T3 (da) | 2012-09-03 |
| EP2420226B1 (en) | 2020-03-04 |
| EP2011486A1 (en) | 2009-01-07 |
| EP3714878A1 (en) | 2020-09-30 |
| HRP20120665T1 (hr) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201000437B (en) | Pharmaceutical compositions of rifaximin | |
| SI2011486T1 (sl) | Farmacevtski sestavki rifaksimina | |
| IL247741A0 (en) | pharmaceutical preparations | |
| ZA200900347B (en) | Preparation of pharmaceutical compositions | |
| GB0814695D0 (en) | Pharmaceutical compositions | |
| EP2222313A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| PL2966175T3 (pl) | Kompozycje farmaceutyczne zawierające 17-alfa-propionian korteksolonu | |
| ZA200905134B (en) | Compositions of stable tiacumicins | |
| GB0608724D0 (en) | Novel Pharmaceutical Compositions | |
| EP2146695A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0707127D0 (en) | Pharmaceutical compositions | |
| GB0709811D0 (en) | Pharmaceutical compositions | |
| GB0610322D0 (en) | Novel pharmaceutical compositions | |
| SI2002825T1 (sl) | Farmacevtski sestavki, ki obsegajo orlistat | |
| GB0716907D0 (en) | Pharmaceutical powder compositions | |
| GB0712454D0 (en) | Pharmaceutical compositions | |
| GB2454923B (en) | Pharmaceutical compositions | |
| IL201394A0 (en) | Niacin - based pharmaceutical compositions | |
| HU0700755D0 (en) | Pharmaceutical compositions containing capsaicionid | |
| GB0800659D0 (en) | Pharmaceutical Compositions | |
| GB0713794D0 (en) | Novel pharmaceutical compositions | |
| GB0701364D0 (en) | Novel pharmaceutical compositions | |
| GB0701367D0 (en) | Novel pharmaceutical compositions | |
| GB0701368D0 (en) | Novel pharmaceutical compositions | |
| GB0704749D0 (en) | Novel pharmaceutical compositions |